Dr. Arun Singh's focus is on developing novel therapies for patients with sarcomas. In the preclinical setting, he works on elucidating the mechanisms contributing to the promotion of growth in cancer cells and optimizing the use of targeted therapy in specific sarcoma subtypes. The insights gained from these efforts are then translated into the clinic in the form of new drugs in early stage Phase I and II clinical trials for sarcomas where there is an unmet clinical need.
Singh AS, Radu CG, Ribas A. PET imaging of the immune system: immune monitoring at the whole body level. Q J Nucl Med Mol Imaging. 2010 Jun;54(3):281-90.
Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, Ishikawa TO, Lehmann LW, Satyamurthy N, Phelps ME, Herschman HR, Czernin J, Witte ON, Radu CG. Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5551-6. Epub 2009 Dec 31.
Singh AS, Chau CH, Price DK, Figg WD. Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer. Nat Clin Pract Urol. 2005 Feb;2(2):101-7.
Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J, Figg WD, Sparreboom A. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol. 2004 Aug;44(8):854-60.
Macpherson GR, Singh AS, Bennett CL, Venzon DJ, Liewehr DJ, Franks ME, Dahut WL, Kantoff PW, Price DK, Figg WD. Genotyping and functional analysis of the D104N variant of human endostatin. Cancer Biol Ther. 2004 Dec;3(12):1298-303. Epub 2004 Dec 16.